MNOV - MediciNova, Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• MediciNova rises ~9% after hours on Canadian nod to start long COVID-19 treatment trial
• MediciNova completes enrollment in mid-stage study of drug for alcohol use disorder
• MediciNova to get Canadian patent linked to potential skin disorder therapy
• MediciNova to get patent in Brazil for cholesterol lowering therapy
• MediciNova to get US patent for MN-166 to treat brain cancer
• MediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disorders
• MediciNova's MN-166 to be part of study to treat Long COVID
• MediciNova begins study of parenteral formulation of MN-166
• MediciNova announces extension of BARDA contract for Ibudilast development
• MediciNova announces MN-001 research alliance with Juntendo University
• MediciNova meets key goal in mid-stage trial for COVID-19 therapy
• MediciNova reports secondary analysis of MN-166 for alcohol use disorder
• MediciNova nabs new patent in Korea for MN-001 for treatment of blood cholesterol
• MediciNova stock jumps after securing Canadian patent for MN-001/002 for hepatic ballooning
• MediciNova receives new European patent for ibudilast for alcohol use disorder
• MediciNova secures new European patent for MN-001 and MN-002 for hepatic ballooning
• MediciNova gains 13% after securing new U.S. patent for MN-166 and riluzole
• MediciNova EPS in-line
• MediciNova secures new U.S. patent for MN-166 in ophthalmic disease; shares up 9%
• MediciNova plans mouse study of MN-166 in chlorine gas-induced lung injury